







































How did COVID-19 affect medical and cardiology journals?
A pandemic in literature
Andrea Venturellia, Marco Vitoloa,b, Alessandro Albinia and Giuseppe Boriania
Background and aims The spreading speed of the COVID-
19 pandemic forced the medical community to produce
efforts in updating and sharing the evidence about this new
disease, trying to preserve the accuracy of the data but at
the same time avoiding the potentially harmful delay from
discovery to implementation. The aim of our analysis was to
assess the impact of the COVID-19 pandemic on medical
literature in terms of proportion of COVID-19-related
published papers and temporal patterns of publications
within a sample of general/internal medicine and cardiology
journals.
Methods We searched through PubMed scientific papers
published from 1 January 2020 to 31 January 2021 about
COVID-19 in ten major medical journals, of which five were
in general/internal medicine and five in the cardiology field.
We analyzed the proportion of COVID-19-related papers,
and we examined temporal trends in the number of
published papers.
Results Overall, the proportion of COVID-19-related papers
was 18.5% (1986/10 756). This proportion was higher
among the five selected general/internal medicine journals,
compared with cardiology journals (23.8% vs 9.5%). The
vast majority of papers were not original articles; in
particular, in cardiology journals, there were 28% ‘original
articles’, 17% ‘review articles’ and 55.1% ‘miscellaneous’,
compared with 20.2%, 5.1% and 74.7% in general/internal
medicine journals, respectively.
Conclusions Our analysis highlights the big impact of the
COVID-19 pandemic on international scientific literature.
General and internal medicine journals were mainly
involved, with cardiology journals only at a later time.
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Introduction
In December 2019, a growing number of reports about a
pneumonia cluster of unknown origin from Wuhan,
China appeared in medical literature.1 Soon, a novel
coronavirus was identified as the etiologic agent of these
unusual cases.2 From that time, the ongoing coronavirus
disease 19 (COVID-19) pandemic has caused more than
144 million confirmed cases of COVID-19, and more than
3 million deaths worldwide, at the time of 23 April 2021.3
The spreading speed of the COVID-19 pandemic forced
the medical community to produce efforts in updating
and sharing new evidence about this disease, trying to
preserve the accuracy of the data but at the same time
avoiding the potentially harmful delay from discovery to
implementation.4–6 Scientists and healthcare workers
had to face this ‘pandemic in literature’ to always keep
up-to-date. At the same time, scientific evidence rapidly
became the main tool to guide political, social and
economic decisions that directly involved billions of
people worldwide. For these reasons, the median time
to publication of COVID-19-related articles has been
shown to be much shorter compared with non-COVID-
19-related articles.7
COVID-19 primarily involved emergency medicine, pul-
monology and intensive care specialists, but soon cardi-
ology departments too had to face the direct effect of the
new coronavirus on the cardiovascular system and the
impact of the pandemic on daily clinical activity.8–12
The aim of our analysis was to assess the impact of the
COVID-19 pandemic on medical literature in terms of
the proportion of COVID-19-related published papers
and temporal patterns of publication within a sample of
general/internal medicine and cardiology journals.
Methods
Search strategy and studies selection
We conducted a review of scientific papers published
from 1 January 2020 to 31 January 2021 about COVID-19
in ten major medical journals. We selected the journals
based on their impact factor, choosing between those
with top-ranking positions, both in the field of medicine
and in the field of cardiology. Also, since Italy was the first
country involved in the pandemic outside of China, we
selected two journals with an important Italian tradition
and a series of contributions on COVID-19: one in the
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medical field, and one in the cardiology field, respec-
tively. We selected the following journals: The New
England Journal of Medicine (NEJM), The Lancet,
Journal of the American Medical Association (JAMA),
American Journal of Medicine (AJM), European Journal
of Internal Medicine (EJIM) for general and internal
medicine; Circulation, European Heart Journal (EHJ),
Journal of the American College of Cardiology (JACC),
Heart and Journal of Cardiovascular Medicine (JCM)
for cardiology.
First, we calculated the total number of publications in
the aforementioned journals during the analyzed period
(from 1 January 2020 to 31 January 2021).
Second, we performed a selective literature search
through PubMed using the following keywords:
‘SARS-CoV 2’, ‘COVID’, ‘COVID-19’ and their related
terms in the same journals and for the same period.
Two investigators (A.V. and A.A.) independently
screened records for eligibility based on title and
abstracts. Two senior reviewers (M.V. and G.B.) inde-
pendently analyzed the study selection and the data
extraction process.
Data analysis
We calculated the proportion of COVID-19-related
papers in the total number of scientific papers pub-
lished. Screened articles on COVID-19 were catego-
rized as follows: ‘original article’ (including research
letter and meta-analysis), ‘review article’ (including
narrative and systematic review, position paper, consen-
sus statements, guidelines) and ‘miscellaneous articles’
(including commentaries/editorials, opinion papers,
viewpoints, perspectives, case reports, letters and
replies). Corrigendum and retracted articles were
excluded. Thereafter, selected papers were stratified
according to publication date, month by month over the
prespecified period consisting of 13 months.
Finally, since Italy was the first country affected by the
COVID-19 pandemic outside of China, we performed a
specific sub-analysis focusing on two journals that tradi-
tionally have an important number of contributions from
Italy, i.e EJIM for general/internal medicine and JCM
for cardiology.
Results
A total number of 10 756 papers were published in the ten
selected journals during the study period. Overall, 1986
papers regarding COVID-19 (18.5%) were identified after
the exclusion of not pertinent, retracted or corrigendum
articles (Fig. 1).
Proportion of COVID-19-related articles
Among the five selected general/internal medicine jour-
nals 1602 papers were COVID-19-related over a total
number of 6732 published papers (23.8%). In the five
selected cardiology journals, the proportion of COVID-
19-related papers was 9.5% (384/4024). Some differences
among the selected journals were found in the proportion
of COVID-19-related papers (Table 1).
Temporal trends
The analysis of publication temporal trends showed an
exponential rise in the first 6 months of 2020, starting
from the end of January 2020, with some delay of around
2–3 months in cardiology journals compared with gen-
eral/internal medicine journals (Fig. 2). Indeed, the first
COVID-19-related paper appeared in NEJM as Epub
online on 24 January 2020,2 whereas the first in the
cardiology journals group appeared in Circulation as
Epub online on 17 March 2020.8 Publication trends in
general/internal medicine journals revealed a smooth
curve across the entire year 2020, without a real separa-
tion between the first and the second wave of the pan-
demic (Fig. 3). Conversely, in cardiology journals, we
found a peak between April and June 2020, followed by a
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Fig. 1
2011 records identified through
database searching from 1 Jan
2020 to 31 Jan 2021 (PubMed)
Records included in the analysis
(n = 1986)
25 records excluded based on title
and abstact or due to the following
reasons: corrigendum, retracted
articles
Flow diagram of the selection process of COVID-19-related papers.
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fall and a plateau phase with only a mild rise during the
second wave of the pandemic in the late autumn (Fig. 4).
Subgroup analysis
In our analysis, among the total number of 1986 publica-
tions, we identified 367 ‘original articles’ (18%), 72
‘review articles’ (4%) and 1547 papers in the ‘miscella-
neous’ group (78%). On average, in cardiology journals,
there were 99 ‘original articles’ (25.8%), 48 ‘review arti-
cles’ (12.5%) and 237 ‘miscellaneous’ (61.7%), compared
with 268 (16.7%), 24 (1.5%) and 1310 (81.8%) in general/
internal medicine journals, respectively (Fig. 5).
In the sub-analysis specifically focused on the journals with
an important number of Italian contributions, we found that
COVID-19-related papers from Italy (defined as first and/or
the corresponding author from Italy) accounted for 71% (50/
70) and 100% (24/24) in the EJIM and JCM, respectively.
The original contributions published on EJIM6,13–40 (29/
70¼ 41.4%) and JCM41–50 (10/24¼ 41.6%) constituted a
substantial number of the COVID-19-related papers pub-
lished in these journals: higher than what was published in
the other analyzed journals (Fig. 5).
Discussion
In our analysis, we focused on the impact of COVID-19
on medical literature specifically on general/internal
medicine and cardiology journals. As expected, the main
finding of our analysis was that COVID-19 strongly
attracted the attention of the medical community across
the entire year 2020.
A substantial amount of the scientific literature of the
year 2020 was actually dedicated to COVID-19, although
with some differences in temporal trends and number of
published papers between journals dedicated to internal
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Table 1 Total number of papers published from 1 January 2020 to 31 January 2021, with regard to all the fields covered by the specific
journals, papers related to COVID-19 and proportion of COVID-19 in all published papers in the selected period
Journal name Total papers COVID-19-related COVID-19-related/Total
General/internal medicine
The New England Journal of Medicine 1882 472 25.1%
The Lancet 1705 556 32.6%
Journal of the American Medical Association 1836 457 24.9%
The American Journal of Medicine 834 47 5.6%
European Journal of Internal Medicine 475 70 14.7%
Cardiology
Circulation 950 104 10.9%
European Heart Journal 1256 125 10.0%
Journal of the American College of Cardiology 1002 91 9.1%
Heart 591 40 6.8%
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Side-by-side comparison of total number of COVID-19-related papers in general and internal medicine and cardiology journals.
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medicine or cardiology. This finding seems reasonably
related to the fact that COVID-19 primarily involved
emergency physicians, pulmonologists and intensivists
and only in a subsequent period did the growing evidence
of direct involvement of the cardiovascular system force
the cardiology scientific community to focus on this
disease. Indeed, this is well reflected by the delay in
publication in cardiology journals compared with general
and internal medicine journals.
The majority of papers regarding COVID-19 in our
analysis were not reporting the results of clinical studies.
The great number of commentaries, opinion papers and
other ‘narrative’ types of articles was probably due to the
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Temporal trend in COVID-19-related papers in general and internal medicine journals. AJM, American Journal of Medicine; EJIM, European Journal of


































































Temporal trend in COVID-19-related papers in cardiology journals. EHJ, European Heart Journal; JACC, Journal of the American College of
Cardiology; JCM, Journal of Cardiovascular Medicine.
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initial lack of data about effective treatments, and due to
the extraordinary impact not only on the healthcare
system but also on social and economic factors. On
average, the relative proportion of original articles is
higher in cardiology journals, as compared with general
and internal medicine journals where a large proportion
of contributions were reviews, commentaries/editorials,
opinion papers etc. Interestingly, original articles consti-
tute a relevant part of the total published papers in the
two journals of Italian tradition that we analyzed in our
sub-analysis (JCM, EJIM), with the highest proportion
among all the selected journals (41.7% in JCM and 41.4%
in EJIM).
This high proportion in original articles among cardiology
journals can be also the effect of the urgent need to obtain
data to manage the complex setting regarding both
patients with COVID-19 developing cardiovascular com-
plications and patients with cardiovascular diseases being
infected by the coronavirus and developing COVID-19.
Some of these publications analyzed the implications of
the COVID-19 pandemic on the organization of care in
the community and reported a reduction in ST-segment
elevation myocardial infarction (STEMI) admissions dur-
ing the pandemic,44 as well as the impact of the pandemic
on interventional activities for both coronary and
electrophysiological procedures.46,50
Similarly, a reduction in the number of heart failure
hospitalizations has also been observed, with a conse-
quent worsening of prognosis.51–54 Possible explications
may be attributable to the patient’s fear of going to
hospital with a delayed time to admission and therefore
to a more advanced heart failure status. Also, modifica-
tions of hospital services and resources towards COVID-
19 treatments could have left patients without usual care
for their specific diseases. These analyses highlight how a
pandemic can affect the severity, morbidity and mortality
of patients without COVID-19 but with a serious medical
condition, like heart failure.
At the same time, among patients with an implantable
cardioverter defibrillator (ICD), a reduction in ventricular
arrhythmias and ICD interventions during the period of
the pandemic compared with the same period of the
previous year was reported.9,55 Indeed, a reduction in
the frequency of some manifestations of cardiovascular
disease was observed during COVID-19, such as acute
myocardial infarction56 or heart failure,57 but on the other
hand an increase in out-of-hospital cardiac arrests, asso-
ciated with reduced survival was observed.58 These find-
ings further underline how complex the interaction is
between different factors involving health of the popula-
tion during COVID-19. Environmental factors, such as air
pollution; social factors, such as lockdown, working and
job changes; and emotional factors all acted in combina-
tion producing different effects that will be better under-
stood only with longitudinal studies.
We also observed that, among the included papers regard-
ing COVID-19, the most covered issues changed over
time. At the beginning of the pandemic, the most frequent





































Types of COVID-19 related papers
Different types of COVID-19-related papers among the selected journals: ‘original papers’, ‘review papers’ and ‘miscellaneous papers’ (i.e.
commentaries/editorials, opinion papers, viewpoints, perspectives, case reports, letters and replies). AJM, American Journal of Medicine; EHJ,
European Heart Journal; EJIM, European Journal of Internal Medicine; JACC, Journal of the American College of Cardiology; JAMA, Journal of the
American Medical Association; JCM, Journal of Cardiovascular Medicine; NEJM, The New England Journal of Medicine.
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topics were about the disease, its clinical features and its
prognostic and therapeutic implications.12,59–63 Subse-
quently, the scientific research focused on the pathophysi-
ology and molecular mechanism,64,65 and finally the
interest of literature moved towards epidemiological and
social implications, with a specific interest also in the
impact of COVID-19 in healthcare organization and sci-
entific research.66–71 Interestingly, this pattern of the
issues of papers fits the evolution over time of a pandemic;
first the focus on the disease itself with the effort to limit
the diffusion and the mortality, then the insights about
molecular mechanisms and the development of therapeu-
tic options, and finally the effect of the pandemic on the
different aspects of society and the scientific world.
It has been reported how the COVID-19 pandemic led to
an unprecedented rise in the production of scientific
papers, with a tendency to accelerate the process of
publication as shown by the high number of scientific
contributions presented as preprint before peer review.72
The low rate of publications for contributions presented
as preprint (<6%) raises concern about the scientific
value of the same contributions proposed during the
COVID-19 pandemic and this phenomenon surely
requires some form of regulation in the future. Also,
the issue of article withdrawals from some top-ranked
journals73,74 suggests that the traditional process of peer
review may have been challenged by the pressures
exerted by a disruptive phenomenon such as the
COVID-19 pandemic. The same pressure acted on the
use of social media, widely used for disseminating scien-
tific information during the pandemic.75 It appears that
the pandemic markedly affected the process of the eval-
uation and presentation of scientific contributions76 and
this had a variable impact on journals in the field of
general and internal medicine, whose future dynamics
need to be carefully monitored.
The scientific community therefore must be aware of the
risks related to the need for rapid publishing and should
always pursue the good practices of the editorial process.
This issue of maintaining a high-quality standard of
scientific publications during the pandemic has raised
particular interest. As reported, our analysis shows that in
the fields of both cardiology and general/internal medi-
cine, original papers were only a fraction of the total
number of publications in these fields, since a large
number of the publications during the year 2020 were
actually editorials, reviews or commentaries. This finding
extends a previous observation limited to the first
4 months of year 2020.77
During the pandemic, even more than at other times, the
risk of misleading or confounding information due to the
need for rapid data sharing could be relevant. As a matter
of fact, we found a not negligible number of retracted and
corrigendum articles (seven and nine, respectively).
Some of these articles dealt directly with cardiologic
treatments in patients with COVID-19, e.g. the use of
angiotensin-converting enzyme inhibitors and angioten-
sin II receptor blockers.78 Other examples are studies
about the use and efficacy of hydroxychloroquine or
chloroquine, or tobacco smoking and the severity of
COVID-19.79,80
In this situation, the scientific community should be
targeted to provide reliable information following the
best contributions of scientists through evidence-
based medicine.
Limitations
This study is based on the analysis of a sample of ten
medical journals that are of course not fully representa-
tive of all scientific literature. We also selected these
journals arbitrarily based on their reputation and impor-
tance in their field, as well as based on their Italian
tradition and contributions, specifically for EJIM and
JCM. Also, the period of time considered is limited to
13 months, excluding the first months of 2021. Another
limitation is linked to the categorization of papers: we put
together different types of articles in the ‘review’ and
‘miscellaneous’ groups, favouring a simple and clear way
to display the results instead of their fragmentation in
many sub-types.
Conclusion
Our analysis showed how international scientific literature
has been significantly involved in the COVID-19 pan-
demic. Particularly, a relevant impact occurred in general
and internal medicine journals, but original studies were
proportionally more prevalent in cardiology journals. With
such an explosion of articles of different nature, aim and
type, and being that the vast majority of publications are
not original articles, it appears that COVID-19 induced a
pandemic also in the medical literature.
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